Marinus Pharmaceuticals Inc MRNS:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 04/24/24 EDT
1.44UNCH (UNCH)
Volume
196,768
Close
1.44UNCH (UNCH)
Volume
1,325,537
52 week range
1.11 - 11.26
Loading...
  • Open1.44
  • Day High1.46
  • Day Low1.39
  • Prev Close1.44
  • 52 Week High11.26
  • 52 Week High Date01/08/24
  • 52 Week Low1.11
  • 52 Week Low Date04/16/24

Key Stats

  • Market Cap79.101M
  • Shares Out54.93M
  • 10 Day Average Volume8.35M
  • Dividend-
  • Dividend Yield-
  • Beta1.11
  • YTD % Change-86.75

KEY STATS

  • Open1.44
  • Day High1.46
  • Day Low1.39
  • Prev Close1.44
  • 52 Week High11.26
  • 52 Week High Date01/08/24
  • 52 Week Low1.11
  • 52 Week Low Date04/16/24
  • Market Cap79.101M
  • Shares Out54.93M
  • 10 Day Average Volume8.35M
  • Dividend-
  • Dividend Yield-
  • Beta1.11
  • YTD % Change-86.75

RATIOS/PROFITABILITY

  • EPS (TTM)-2.63
  • P/E (TTM)-0.55
  • Fwd P/E (NTM)-0.65
  • EBITDA (TTM)-130.934M
  • ROE (TTM)-219.71%
  • Revenue (TTM)30.989M
  • Gross Margin (TTM)93.76%
  • Net Margin (TTM)-456.31%
  • Debt To Equity (MRQ)435.28%

EVENTS

  • Earnings Date05/09/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Marinus Pharmaceuticals Inc

 

Profile

MORE
Marinus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus, which includes the use of ZTALMY (ganaxolone). Its U.S. Food and Drug Administration (FDA) approved the Company’s new drug application for the use of ZTALMY oral suspension CV for the treatment of seizures associated with...
Scott Braunstein M.D.
Chairman of the Board, President, Chief Executive Officer
Steven Pfanstiel
Chief Financial Officer, Chief Operating Officer, Treasurer
Address
Three Radnor Corporate Center
100 Matsonford Rd, Suite 304
Radnor, PA
19087
United States

Top Peers

SYMBOLLASTCHG%CHG
ACRS
Aclaris Therapeutics Inc
1.17UNCHUNCH
TKNO
Alpha Teknova Inc
1.71UNCHUNCH
PRE
Prenetics Global Ltd
4.79UNCHUNCH
EQ
Equillium Inc
1.79UNCHUNCH
HOOK
HOOKIPA Pharma Inc
0.85UNCHUNCH